Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction

[1]  P. Ponikowski,et al.  Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. , 2020, The New England journal of medicine.

[2]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[3]  J. Rouleau,et al.  Care Gaps in Adherence to Heart Failure Guidelines: Clinical Inertia or Physiological Limitations? , 2020, JACC. Heart failure.

[4]  M. Metra,et al.  Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejection fraction , 2020, European journal of heart failure.

[5]  G. Fonarow,et al.  Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction , 2020, Circulation. Heart failure.

[6]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[7]  G. Fonarow,et al.  Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. , 2019, JAMA cardiology.

[8]  L. Tavazzi,et al.  Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. , 2019, JACC. Heart failure.

[9]  Dave L Dixon,et al.  Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. , 2019, Journal of the American College of Cardiology.

[10]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[11]  G. Linssen,et al.  Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015 , 2019, Heart Failure Reviews.

[12]  Zi-Xin Zhang,et al.  Quality of life and outcomes in heart failure patients with ejection fractions in different ranges , 2019, PloS one.

[13]  B. Bozkurt.  Reasons for Lack of Improvement in Treatment With Evidence-Based Therapies in Heart Failure. , 2019, Journal of the American College of Cardiology.

[14]  J. H. Patterson,et al.  Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[15]  I. Hamour,et al.  A per‐protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region , 2019, ESC heart failure.

[16]  J. McMurray,et al.  Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients , 2019, PLoS medicine.

[17]  Y. Niriayo,et al.  Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia , 2019, BioMed research international.

[18]  A. F. Fonseca,et al.  Real‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany , 2019, European journal of heart failure.

[19]  P. Ponikowski,et al.  Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry , 2019, European journal of heart failure.

[20]  Mahesh J. Patel,et al.  Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[21]  F. McAlister,et al.  Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice , 2019, Journal of cardiovascular pharmacology.

[22]  J. Álvarez-García,et al.  Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review , 2019, Cardiovascular Drugs and Therapy.

[23]  D. Smith,et al.  Beta-blocker target dosing and tolerability in a dedicated heart failure clinic in Johannesburg. , 2019, Cardiovascular journal of Africa.

[24]  L. Vicent,et al.  Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry , 2018, Journal of cardiovascular pharmacology.

[25]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[26]  W. Shimizu,et al.  Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. , 2018, The Lancet. Global health.

[27]  M. Sénéchal,et al.  Usefulness of a titration algorithm for de novo users of sacubitril/valsartan in a tertiary centre heart failure clinic. , 2018, Cardiovascular journal of Africa.

[28]  Akshay S. Desai,et al.  Reasons for Guideline Nonadherence at Heart Failure Discharge , 2018, Journal of the American Heart Association.

[29]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[30]  S. Byrne,et al.  A tool for assessment of heart failure prescribing quality: A systematic review and meta‐analysis , 2018, Pharmacoepidemiology and drug safety.

[31]  J. H. Patterson,et al.  Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial , 2018, Journal of the American Heart Association.

[32]  S. Stemkowski,et al.  An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction , 2018, Advances in Therapy.

[33]  M. Hochadel,et al.  Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy , 2018, Clinical Research in Cardiology.

[34]  S. W. Asgedom,et al.  Treatment optimization of angiotensin converting enzyme inhibitors and associated factors in Ayder Comprehensive Specialized Hospital: a cross-sectional study , 2018, BMC Research Notes.

[35]  G. Felker,et al.  Outpatient Worsening Heart Failure as a Target for Therapy: A Review , 2018, JAMA cardiology.

[36]  P. Martens,et al.  Insights into implementation of sacubitril/valsartan into clinical practice , 2018, ESC heart failure.

[37]  L. E. Davis,et al.  Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic , 2018, American Journal of Cardiovascular Drugs.

[38]  C. Reid,et al.  Mind the Gap: Mismatches Between Clinicians and Patients in Heart Failure Medication Management , 2018, Cardiovascular Drugs and Therapy.

[39]  Hung-Yu Chang,et al.  Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC‐HFrEF registry , 2017, Journal of the Chinese Medical Association : JCMA.

[40]  P. Ponikowski,et al.  Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF , 2017, European journal of heart failure.

[41]  W. Kraus,et al.  Multinational and multiethnic variations in health‐related quality of life in patients with chronic heart failure , 2017, American heart journal.

[42]  M. Lelonek,et al.  Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey. , 2017, Polish archives of internal medicine.

[43]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[44]  B. Davidson,et al.  Improving heart failure patient outcomes utilizing guideline-directed therapy , 2017, The Nurse practitioner.

[45]  P. Ponikowski,et al.  Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study , 2017, European heart journal.

[46]  P. Ponikowski,et al.  Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry , 2017, European journal of heart failure.

[47]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of cardiac failure.

[48]  F. Verbrugge,et al.  Feasibility and Association of Neurohumoral Blocker Up-titration After Cardiac Resynchronization Therapy. , 2017, Journal of cardiac failure.

[49]  J. McMurray,et al.  Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction , 2017, Circulation. Heart failure.

[50]  Gianluigi Savarese,et al.  Global Public Health Burden of Heart Failure. , 2016, Cardiac failure review.

[51]  C. Reid,et al.  The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice , 2016, Heart Failure Reviews.

[52]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[53]  H. van den Bussche,et al.  General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study , 2016, Clinical Research in Cardiology.

[54]  M. Munger,et al.  Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center , 2016, Pharmacotherapy.

[55]  I. Piña,et al.  Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. , 2016, JACC. Heart failure.

[56]  A. Bayés‐Genís,et al.  Adherence to the ESC Heart Failure Treatment Guidelines in Spain: ESC Heart Failure Long-term Registry. , 2015, Revista espanola de cardiologia.

[57]  M. Dunlap,et al.  Adherence to clinical guidelines in heart failure (HF) outpatients: Impact of an interprofessional HF team on evidence-based medication use , 2015, Journal of interprofessional care.

[58]  M. Petzold,et al.  Does the target dose of neurohormonal blockade matter for outcome in Systolic heart failure in octogenarians? , 2015, International journal of cardiology.

[59]  D. Francis,et al.  The annual global economic burden of heart failure. , 2014, International journal of cardiology.

[60]  W. Kraus,et al.  Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. , 2012, Journal of the American College of Cardiology.

[61]  J. McMurray,et al.  Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. , 2011, Journal of the American College of Cardiology.

[62]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[63]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[64]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[65]  E. Salpeter,et al.  Cardioselective beta-blockers for chronic obstructive pulmonary disease. , 2005, The Cochrane database of systematic reviews.

[66]  E. Salpeter,et al.  Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. , 2003, Respiratory medicine.

[67]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[68]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[69]  A. Hoes,et al.  Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry. , 2019, JACC. Heart failure.

[70]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[71]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.